Vascular Inflammation and Cholesterol Lowering Therapy

• Status: Withdrawn
• Trial end date: 2020-10-01
• Target enrollment: 0
• Participant gender: All

Summary

This study aim to detect change in vascular inflammation following intense lipid lowering therapy

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Rigshospitalet, Denmark
• Treatments: Evolocumab

Criteria

Inclusion Criteria:

• treatment with PCSK-9 inhibitors

Exclusion Criteria:

• Infection Pregnancy Severe claustrophobia Weight >140 kg